Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fulvestrant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 10/20 | 0.76 |
| ▸ | ESRRA | P11474 | 9/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.76 |
| ▸ | PPARG | P37231 | 1/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.76 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ESRRB | O95718 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fulvestrant SCHEMBL8427428 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL408338 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL14340043 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL22356606 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL23134939 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL20448785 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL23760281 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| SCHEMBL24511123 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| SCHEMBL23963146 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL22667548 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 62476 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079776-A | Method for synthesizing fulvestrant intermediate by utilizing pentafluoroethane photocatalysis and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094678-A | AP 2-related kinase 1 inhibitors and uses thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| US-12630593-B2 | Method of killing leukemia cells by administration of recombinant'Y3 proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-19 | — | — | US | claimed |
| WO-2001047451-A1 | APPARATUS AND METHOD FOR DELIVERING COMPOUNDS TO A LIVING ORGANISM | NEW GISHEL (US) | 2001-07-05 | — | — | WO | claimed |
| US-6204258-B1 | ENHANCING HAIR GROWTH OR TREATING ALOPECIA IN A SUBJECT USES TOPICALLY ADMINISTERED ESTROGEN RECEPTOR ANTAGONISTS. | NORTH CAROLINA STATE UNIVERSITY | 2001-03-20 | — | — | US | claimed |
| EP-1058545-A1 | CANCER MANAGEMENT WITH TAMOXIFEN AND GAMMALINOLENIC ACID | SCOTIA HOLDINGS PLC (GB) | 2000-12-13 | — | — | EP | claimed |
| WO-2000042841-A1 | METHODS FOR IDENTIFYING, TREATING OR MONITORING ASYMPTOMATIC PATIENTS FOR RISK REDUCTION OR THERAPEUTIC TREATMENT OF BREAST CANCER | PRO-DUCT HEALTH, INC. (US) | 2000-07-27 | — | — | WO | claimed |
| US-5965551-A | Method of treating alopecia | NORTH CAROLINA STATE UNIVERSITY (US) | 1999-10-12 | — | — | US | claimed |
| WO-1999044600-A1 | CANCER MANAGEMENT WITH TAMOXIFEN AND GAMMALINOLENIC ACID | SCOTIA HOLDINGS PLC (GB) | 1999-09-10 | — | — | WO | claimed |
| WO-1996035417-A1 | COMBINATIONS OF ANTI-OESTROGEN COMPOUNDS AND PKC MODULATORS AND THEIR USE IN CANCER THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-11-14 | — | — | WO | claimed |
| EP-0346014-B1 | Therapeutic product for the treatment of peri- or postmenopausal conditions | ZENECA LTD (GB) | 1994-08-03 | — | — | EP | claimed |
| US-5183814-A | Administering estrogen and antiestrogen | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-02 | — | — | US | claimed |
| EP-0346014-A1 | Therapeutic product for the treatment of peri- or postmenopausal conditions | ZENECA LIMITED (GB) | 1989-12-13 | — | — | EP | claimed |